We are very sorry but it looks like you are using an outdated browser. We strongly recommend updating to a modern browser.
More information about your browser and how to update

Cellectis Bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008, and provides life science researchers with targeted integration products based on Meganuclease-driven Homologous Recombination.

Since its inception in 1999, Cellectis has been a pioneer in the field of genome engineering. Our parent company has extensive experience on meganucleases, meganuclease engineering, TALE Nuclease technology and expertise in biological repair mechanisms such as Homologous Recombination.

Meganucleases are highly specific DNA endonucleases that enable precise modifications of genomic DNA, with applications in the research, bioproduction, agrobiotechnology, and therapeutic sectors.
Since recently Cellectis Bioresearch also offers the new tool called TALEN®'s. A new technology enabling all our customers to do genome customization at any position, at will in any organism or cell line.

Details


Address:
Cellectis Bioresearch

rue de la Croix Jarry 8
75013 Paris
France
Field of Activity:
Clinical Research
Hospital & Medical Practice
Other Activities
Research & Development
Research & Education
Sales
Expansion:
international
Number of employess:
51-500
Founding year:
1999